Design of Turmeric Rhizome Extract Nano-Formula for Delivery to Cancer Cells
Issued Date
2022-02-01
Resource Type
eISSN
14203049
Scopus ID
2-s2.0-85123635101
Pubmed ID
35164159
Journal Title
Molecules
Volume
27
Issue
3
Rights Holder(s)
SCOPUS
Bibliographic Citation
Molecules Vol.27 No.3 (2022)
Suggested Citation
Auychaipornlert S., Lawanprasert P.P., Piriyaprasarth S., Sithisarn P., Mangmool S. Design of Turmeric Rhizome Extract Nano-Formula for Delivery to Cancer Cells. Molecules Vol.27 No.3 (2022). doi:10.3390/molecules27030896 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/83845
Title
Design of Turmeric Rhizome Extract Nano-Formula for Delivery to Cancer Cells
Author's Affiliation
Other Contributor(s)
Abstract
Novel turmeric rhizome extract nanoparticles (TE-NPs) were developed from fractions of dried turmeric (Curcuma longa Linn.) rhizome. Phytochemical studies, by using HPLC and TLC, of the fractions obtained from ethanol extraction and solvent–solvent extraction showed that turmeric rhizome ethanol extract (EV) and chloroform fraction (CF) were composed mainly of three curcuminoids and turmeric oil. Hexane fraction (HE) was composed mainly of turmeric oil while ethyl acetate fraction (EA) was composed mainly of three curcuminoids. The optimal TE-NPs formulation with particle size of 159.6 ± 1.7 nm and curcumin content of 357.48 ± 8.39 µM was successfully developed from 47-run D-optimal mixture–process variables experimental design. Three regression models of z-average, d50, and d90 could be developed with a reasonable accuracy of prediction (predicted r2 values were in the range of 0.9120–0.9992). An in vitro cytotoxicity study using MTT assay demonstrated that the optimal TE-NPs remarkably exhibited the higher cytotoxic effect on human hepatoma cells, HepG2, when compared with free curcumin. This study is the first to report nanoparticles prepared from turmeric rhizome extract and their cytotoxic activity to hepatic cancer cells compared with pure curcumin. These nanoparticles might serve as a potential delivery system for cancer therapy.